Velaglucerase Alfa for the Management of Type 1 Gaucher Disease

Clinical Therapeutics

Volumn 34, Issue 2, 2012, Pages 259-271

  Morris, Jennifer L ^a  

^a RILEY HOSPITAL FOR CHILDREN   (United States)

Author keywords

Enzyme replacement therapy; Gaucher disease; Type 1 Gaucher disease velaglucerase alfa

Indexed keywords

ANTIBODY; HEMOGLOBIN; IMIGLUCERASE; VELAGLUCERASE ALFA;

ABDOMINAL PAIN; ANEMIA; ARTHRALGIA; ASTHENIA; BACKACHE; BONE PAIN; COCHRANE LIBRARY; CONVULSION; COUGHING; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EMBASE; ENZYME REPLACEMENT; EPISTAXIS; FATIGUE; FEVER; GAUCHER DISEASE; HEMOGLOBIN DETERMINATION; HEPATOMEGALY; HUMAN; MEDLINE; NAUSEA; PARTIAL THROMBOPLASTIN TIME; PEER REVIEW; REVIEW; SIDE EFFECT; SKIN ALLERGY; SPLENOMEGALY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREMOR; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

CLINICAL TRIALS AS TOPIC; ENZYME REPLACEMENT THERAPY; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HEMOGLOBINS; HUMANS; PLATELET COUNT;

EID: 84856709510     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.12.017     Document Type: Review

References (16)

1. Elstein D., Abrahamov A., Dweck A., et al. Gaucher disease: pediatric concerns. Pediatr Drugs 2002, 4:417-426.
2. Zimran A., Altarescu G., Philips M., et al. Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month extension. Blood 2010, 115:4651-4656.
3. Swarker A.R., D'Haeze W., Kelly J.W. Therapeutic strategies to ameliorate lysosomal storage disorders-a focus on Gaucher disease. Cell Mol Life Sci 2006, 63:1179-1192.
4. Elstein D., Cohn G.M., Wang N., et al. Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease. Blood Cells Mol Dis 2011, 46:119-123.
5. VPRIV (velaglucerase alfa) [prescribing information] 2010, Shire Human Genetic Therapies, Inc, Cambridge, Mass.
6. Lang L. The US Food and Drug Administration approves a new Gaucher disease drug. Gastroenterology 2010, 138:2196.
7. Zimran A., Loveday K., Fratazzi C., Elstein D. A pharmacokinetic analysis of a novel enzyme replacement therapy with gene-activated human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher disease. Blood Cells Mol Dis 2007, 39:115-118.
8. Elstein D., Foldes A.J., Zahrieh D., et al. Significant and continuous improvement in bone mineral density among type 1 Gaucher disease patients treated with velaglucerase alfa: 69-month experience, including dose reduction. Blood Cells Mol Dis 2011, 47:56-61.
9. Study of GA-GCB enzyme replacement therapy in type 1 Gaucher disease in patients previously treated with imiglucerase. ClinicalTrials.gov [Internet] 2000, Shire Human Genetic Therapies, Inc., National Library of Medicine, Bethesda, Md, NLM Identifier: NCT00478647. Accessed November 21, 2011. http://www.clinicaltrials.gov/ct2/show/study/NCT00478647.%20NLM%20Identifier:%20NCT00478647.
10. A study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) enzyme replacement therapy in Gaucher Disease. ClinicalTrials.gov [Internet] 2000, Shire Human Genetic Therapies, Inc., National Library of Medicine, Bethesda, Md, Identifier: NCT00430625. Accessed November 21, 2011. http://www.clinicaltrials.gov/ct2/show/results/NCT00430625.%20Identifier:%20NCT00430625.
11. Zimran A., Gonzalez D., Crombez E., Bhirangi K. Enzyme replacement therapy with velaglucerase alfa significantly improves key clinical parameters in a pediatric subgroup with type 1 Gaucher disease. Mol Genet Metab 2010, 99:S8-S41. Abstract 156.
12. A study of gene-activated® human glucocerebrosidase (GA-GCB) ERT compared with Imiglucerase in type 1 Gaucher disease. ClinicalTrials.gov [Internet] 2000, Shire Human Genetic Therapies, Inc., National Library of Medicine, Bethesda, Md, Identifier: NCT00553631 [HGT-GCB-039]. Accessed November 21, 2011. http://www.clinicaltrials.gov/ct2/show/results/NCT00553631.
13. Pastores G.M., Weinreb N.J., Aerts H., et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 2004, 41:4-14.
14. Elstein D., Altarescu G., Maayan H., et al. Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: Early Access Program results from Jerusalem. Blood Cells Mol Dis 2012, 48:45-50.
15. Ruiz J., Brazegar S., Clarke A., et al. Antigenic differences in patients with type 1 Gaucher disease receiving velaglucerase alfa or imiglucerase enzyme replacement therapy in controlled clinical trials. Haematologica 2010, 95(Suppl 2):75.
16. Xu Y.H., Sun Y., Barnes S., Grabowski G.A. Comparative therapeutic effects of velaglucerase alfa and imiglucerase in a Gaucher disease mouse model. PLoS One 2010, 5:e10750.